Status:

COMPLETED

Evaluation of 18F-fluciclovine (FACBC) PET/MR Uptake in Participants With Glioma

Lead Sponsor:

James Mountz

Collaborating Sponsors:

Blue Earth Diagnostics

Conditions:

Glioma

Eligibility:

All Genders

18+ years

Phase:

EARLY_PHASE1

Brief Summary

This is a pilot study to assess the ability of \[F-18\]fluciclovine to differentiate pseudoprogression from progression in participants after therapy, at imaging time points within the 12 week interva...

Detailed Description

In this pilot study the investigators propose to image 10 participants who have been previously diagnosed by resection or biopsy with grade 3 or 4 glioma. All glioma cases undergoing resection at UPM...

Eligibility Criteria

Inclusion

  • 1\. Age ≥ 18 years old.
  • 2\. Been previously diagnosed by resection or biopsy with grade 3 or 4 glioma.
  • 3\. Agree to use adequate contraception as indicated in this protocol.
  • 4\. Consent to PET scanning and receipt of one injection of 18F-fluciclovine.
  • 5\. Able to comply with study procedures.
  • 6\. Able to give written consent.
  • 7\. Subject has had a standard of care, diagnostic MRI study which was indeterminate due to the inability to differentiate pseudoprogression versus tumor progression.

Exclusion

  • 1\. Are a pregnant or breastfeeding female.
  • 2\. Are participating in a clinical trial of another unlicensed product.
  • 3\. Are undergoing 18F-fluciclovine PET for reason(s) other than newly diagnosed or recurrent glioma.
  • 4\. Have a hypersensitivity to 18F-fluciclovine.
  • 5\. Have acute renal failure or moderate/severe renal impairment, according to local clinical guidelines.
  • 6\. Have a non-MRI compatible implantable device or another contraindication for MRI scan.
  • 7\. Are deemed ineligible to participate for other reasons by an investigator.

Key Trial Info

Start Date :

October 22 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 30 2021

Estimated Enrollment :

9 Patients enrolled

Trial Details

Trial ID

NCT04114370

Start Date

October 22 2019

End Date

September 30 2021

Last Update

December 6 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

UPMC Hospitals

Pittsburgh, Pennsylvania, United States, 15213